David T. Teachey
Children's Hospital of Philadelphia · 677 works · 29,447 citations · h-index 73
Top works
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
- Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
- Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.
- Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2
- Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
- Treatment of E pstein B arr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimens
- The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
- Toxicity management for patients receiving novel T-cell engaging therapies